Donanemab is an antibody drug that targets a modified form of beta amyloid, the same type of toxic protein that Biogen’s Alzheimer’s drug Aduhelm targets. Beta amyloid are believed to destroy the brain.
Eli Lilly is conducting phase 3 studies of the drug in patients with early Alzheimer’s. The drugmaker said in March that a clinical trial of 257 people showed the drug slowed the progression of the disease by 32 percent over 18 months. It also completely removed beta amyloid from the brains of 68 percent of the trial participants after 18 months.
After the news that Eli LIlly plans to file for approval this year, its shares rose more than 8 percent, and Biogen’s fell 5 percent, according to Bloomberg. Paul Matteis, an analyst at Stifel Financial Corp, told Bloomberg that the drugmaker’s move to seek accelerated approval this year “is somewhat surprising to us from a timing perspective.”
But, donanemab’s efficacy data looks good compared to Aduhelm’s and is “less confusing,” Mr. Matteis added. He also said that if Eli Lilly’s drug is approved, it could drive down the price of Aduhelm.
Aduhelm was approved June 7, and the price was set at $56,000 per year.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
